Susan L. Cohn to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Susan L. Cohn has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
2.011
-
Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient. Pediatr Blood Cancer. 2020 08; 67(8):e28218.
Score: 0.364
-
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255.
Score: 0.344
-
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13.
Score: 0.189
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.105
-
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514.
Score: 0.098
-
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189.
Score: 0.095
-
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794.
Score: 0.094
-
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755.
Score: 0.086
-
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124.
Score: 0.082
-
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149.
Score: 0.080
-
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34.
Score: 0.076
-
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56.
Score: 0.068
-
Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014 Jun; 61(6):1104-6.
Score: 0.058
-
Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer. 2014 May; 61(5):949-50.
Score: 0.058
-
Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. Pediatr Blood Cancer. 2013 Mar; 60(3):512-4.
Score: 0.054
-
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8.
Score: 0.052
-
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23.
Score: 0.047
-
Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188.
Score: 0.025
-
Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. Pediatr Blood Cancer. 2017 03; 64(3).
Score: 0.018
-
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10.
Score: 0.017